Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Equity Average (2016 - 2026)

Integra Lifesciences Holdings' Equity Average history spans 16 years, with the latest figure at $1.0 billion for Q4 2025.

  • On a quarterly basis, Equity Average fell 32.14% to $1.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 billion, a 32.14% decrease, with the full-year FY2025 number at $1.3 billion, down 17.38% from a year prior.
  • Equity Average hit $1.0 billion in Q4 2025 for Integra Lifesciences Holdings, roughly flat from $1.0 billion in the prior quarter.
  • Over the last five years, Equity Average for IART hit a ceiling of $1.8 billion in Q4 2022 and a floor of $1.0 billion in Q3 2025.
  • Historically, Equity Average has averaged $1.5 billion across 5 years, with a median of $1.6 billion in 2023.
  • Biggest five-year swings in Equity Average: increased 16.73% in 2021 and later tumbled 32.14% in 2025.
  • Tracing IART's Equity Average over 5 years: stood at $1.7 billion in 2021, then increased by 6.4% to $1.8 billion in 2022, then decreased by 10.25% to $1.6 billion in 2023, then decreased by 3.16% to $1.5 billion in 2024, then tumbled by 32.14% to $1.0 billion in 2025.
  • Business Quant data shows Equity Average for IART at $1.0 billion in Q4 2025, $1.0 billion in Q3 2025, and $1.3 billion in Q2 2025.